| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.92 [0.84, 1.01] | | < 1 | | 3% | 4 studies (4/-) | 96.1 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 0.89 [0.67, 1.18] | | < 1 | | 66% | 3 studies (3/-) | 79.2 % | some concern | not evaluable | moderate | important | - |
| DOR | 0.32 [0.21, 0.49] | | < 1 | | 43% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| objective responses (ORR) | 0.59 [0.31, 1.13] | | > 1 | | 94% | 4 studies (4/-) | 5.6 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.14 [0.05, 0.40] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 0.29 [0.12, 0.71] | | < 1 | | 95% | 3 studies (3/-) | 99.7 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-5) | 1.53 [1.01, 2.33] | | < 1 | | 0% | 1 study (1/-) | 2.3 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 2.36 [1.02, 5.43] | | < 1 | | 67% | 2 studies (2/-) | 2.2 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.72 [0.23, 2.24] | | < 1 | | 97% | 4 studies (4/-) | 71.3 % | some concern | not evaluable | moderate | non important | - |
| SAE (any grade) | 1.10 [0.71, 1.70] | | < 1 | | 84% | 3 studies (3/-) | 33.9 % | some concern | not evaluable | moderate | non important | - |
| STRAE (any grade) | 0.78 [0.42, 1.48] | | < 1 | | 90% | 4 studies (4/-) | 77.3 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.14 [0.06, 0.34] | | < 1 | | 90% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.19 [0.05, 0.77] | | < 1 | | 98% | 4 studies (4/-) | 99.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.12 [0.42, 2.98] | | < 1 | | 0% | 4 studies (4/-) | 41.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 0.78 [0.28, 2.17] | | < 1 | | 88% | 2 studies (2/-) | 68.3 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 2.15 [0.19, 24.47] | | < 1 | | 0% | 2 studies (2/-) | 27.1 % | some concern | not evaluable | moderate | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 1.59 [0.24, 10.48] | | < 1 | | 0% | 2 studies (2/-) | 31.6 % | some concern | not evaluable | moderate | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 2.89 [0.42, 20.04] | | < 1 | | 0% | 3 studies (3/-) | 14.2 % | some concern | not evaluable | moderate | non important | - |
| Alopecia TRAE (grade 3-4) | 1.36 [0.10, 17.71] | | < 1 | | 0% | 2 studies (2/-) | 40.9 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.10 [0.01, 0.75] | | < 1 | | 95% | 4 studies (4/-) | 98.7 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 2.85 [0.26, 30.86] | | < 1 | | 0% | 2 studies (2/-) | 19.6 % | some concern | not evaluable | moderate | non important | - |
| Arthritis TRAE (grade 3-4) | 1.36 [0.10, 17.75] | | < 1 | | 0% | 2 studies (2/-) | 40.8 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.67 [0.37, 1.19] | | < 1 | | 0% | 4 studies (4/-) | 91.4 % | some concern | not evaluable | moderate | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.46 [0.04, 5.04] | | < 1 | | 0% | 2 studies (2/-) | 73.7 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 2.63 [0.49, 14.17] | | < 1 | | 0% | 3 studies (3/-) | 13.1 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.68 [0.09, 4.89] | | < 1 | | 0% | 3 studies (3/-) | 65.0 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.72 [0.29, 1.75] | | < 1 | | 0% | 4 studies (4/-) | 76.8 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 1.55 [0.20, 12.06] | | < 1 | | 0% | 3 studies (3/-) | 33.7 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.12 [0.50, 2.52] | | < 1 | | 19% | 3 studies (3/-) | 38.8 % | some concern | not evaluable | moderate | non important | - |
| Dyspnoea TRAE (grade 3-4) | 2.15 [0.19, 24.47] | | < 1 | | 0% | 2 studies (2/-) | 27.1 % | some concern | not evaluable | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 0.64 [0.33, 1.23] | | < 1 | | 4% | 4 studies (4/-) | 90.9 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.24 [0.04, 1.44] | | < 1 | | 0% | 2 studies (2/-) | 94.1 % | some concern | not evaluable | moderate | non important | - |
| Gastritis TRAE (grade 3-4) | 1.36 [0.10, 17.75] | | < 1 | | 0% | 2 studies (2/-) | 40.8 % | some concern | not evaluable | moderate | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 1.36 [0.10, 17.71] | | < 1 | | 0% | 2 studies (2/-) | 40.9 % | some concern | not evaluable | moderate | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.88 [0.44, 18.77] | | < 1 | | 0% | 3 studies (3/-) | 13.6 % | some concern | not evaluable | moderate | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 0.46 [0.04, 5.04] | | < 1 | | 0% | 2 studies (2/-) | 73.7 % | some concern | not evaluable | moderate | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.24 [0.14, 10.64] | | < 1 | | 0% | 3 studies (3/-) | 42.3 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 3.78 [0.59, 24.42] | | < 1 | | 0% | 3 studies (3/-) | 8.2 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 2.71 [0.40, 18.39] | | < 1 | | 0% | 3 studies (3/-) | 15.5 % | some concern | not evaluable | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 1.36 [0.38, 4.94] | | < 1 | | 0% | 2 studies (2/-) | 31.9 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.76 [0.55, 13.71] | | < 1 | | 0% | 2 studies (2/-) | 10.8 % | some concern | not evaluable | moderate | non important | - |
| Increased lipase level TRAE (grade 3-4) | 10.14 [2.36, 43.58] | | < 1 | | 0% | 2 studies (2/-) | 0.1 % | some concern | not evaluable | moderate | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.91 [0.06, 14.64] | | < 1 | | 0% | 2 studies (2/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.14 [0.01, 1.41] | | < 1 | | 73% | 3 studies (3/-) | 95.2 % | some concern | not evaluable | moderate | non important | - |
| Myocarditis TRAE (grade 3-4) | 2.08 [0.29, 15.06] | | < 1 | | 0% | 3 studies (3/-) | 23.5 % | some concern | not evaluable | moderate | non important | - |
| Myositis TRAE (grade 3-4) | 1.23 [0.14, 10.56] | | < 1 | | 0% | 3 studies (3/-) | 42.5 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.28 [0.07, 1.10] | | < 1 | | 44% | 4 studies (4/-) | 96.5 % | some concern | not evaluable | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 2.43 [0.36, 16.23] | | < 1 | | 0% | 3 studies (3/-) | 18.1 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.04 [0.00, 0.95] | | < 1 | | 90% | 4 studies (4/-) | 97.5 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 2.71 [0.40, 18.39] | | < 1 | | 0% | 3 studies (3/-) | 15.5 % | some concern | not evaluable | moderate | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.11 [0.01, 0.91] | | < 1 | | 0% | 2 studies (2/-) | 97.9 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.81 [0.56, 14.10] | | < 1 | | 0% | 3 studies (3/-) | 10.5 % | some concern | not evaluable | moderate | non important | - |
| Pruritic rash TRAE (grade 3-4) | 1.36 [0.10, 17.75] | | < 1 | | 0% | 2 studies (2/-) | 40.8 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 2.91 [0.56, 15.17] | | < 1 | | 0% | 4 studies (4/-) | 10.3 % | some concern | not evaluable | moderate | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.62 [0.12, 3.24] | | < 1 | | 0% | 2 studies (2/-) | 71.6 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 4.56 [1.16, 18.02] | | < 1 | | 0% | 4 studies (4/-) | 1.5 % | some concern | not evaluable | moderate | non important | - |
| Sarcoidosis TRAE (grade 3-4) | 0.98 [0.02, 49.53] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Sepsis TRAE (grade 3-4) | 0.69 [0.08, 5.93] | | < 1 | | 0% | 2 studies (2/-) | 63.1 % | some concern | not evaluable | moderate | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 3.99 [0.84, 18.92] | | < 1 | | 0% | 1 study (1/-) | 4.1 % | NA | not evaluable | | non important | - |
| Stevens-Johnson syndrome TRAE (grade 3-4) | 1.36 [0.10, 17.71] | | < 1 | | 0% | 2 studies (2/-) | 40.9 % | some concern | not evaluable | moderate | non important | - |
| Stomatitis TRAE (grade 3-4) | 1.36 [0.10, 17.75] | | < 1 | | 0% | 2 studies (2/-) | 40.8 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.09 [0.01, 0.82] | | < 1 | | 83% | 4 studies (4/-) | 98.3 % | some concern | not evaluable | moderate | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.23 [0.14, 10.57] | | < 1 | | 0% | 3 studies (3/-) | 42.5 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 0.54 [0.16, 1.82] | | < 1 | | 41% | 3 studies (3/-) | 84.1 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| Anaemia AE (grade 3-4) | 0.08 [0.05, 0.13] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.51 [0.24, 1.10] | | < 1 | | 0% | 1 study (1/-) | 95.7 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.22 [0.09, 0.54] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Febrile neutropenia AE (grade 3-4) | 0.05 [0.00, 0.92] | | < 1 | | 0% | 1 study (1/-) | 97.7 % | NA | not evaluable | | non important | - |
| Hypertension AE (grade 3-4) | 0.54 [0.18, 1.61] | | < 1 | | 0% | 1 study (1/-) | 86.4 % | NA | not evaluable | | non important | - |
| Leucopenia AE (grade 3-4) | 0.02 [0.00, 0.25] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.08 [0.01, 0.58] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 0.00 [0.00, 0.05] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.01 [0.00, 0.10] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.10 [0.01, 0.76] | | < 1 | | 0% | 1 study (1/-) | 98.6 % | NA | not evaluable | | non important | - |
